exRNAdisease

Entry Detail

---



General Information

Database ID: exR0356641 RNA Name: hsa-miR-299-3p RNA Type: miRNA Chromosome: chr14 Starnd: + Coordinate: Start Site(bp): 101023832 End Site(bp): 101023853 External Links: hsa-miR-299-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE98181 Description: Circulating miRNA profiles from serum of women at high-risk for breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: NA Case Sample: Breast Cancer Control Sample: Healthy Number of Case: 24 Number of Control: 24 Number of Samples: 48

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand AFF4 chr5 132875395 132963634 - AK2 chr1 33007940 33080996 - AP3M1 chr10 74120255 74151063 - ARCN1 chr11 118572390 118603033 + CASP2 chr7 143288215 143307696 + CMIP chr16 81445170 81711762 + COL4A2 chr13 110305812 110513209 + CORO2B chr15 68578993 68727806 + DHX33 chr17 5440917 5468982 - DNAJC9 chr10 73183362 73247255 - E2F6 chr2 11444375 11466177 - FHL2 chr2 105357712 105438513 - GLCCI1 chr7 7968796 8094272 + LY6E chr8 143017982 143023832 + MAP3K14 chr17 45263119 45317029 - MAP3K2 chr2 127298730 127388465 - MAP3K20 chr2 173075435 173268015 + MBNL1 chr3 152243828 152465780 + MPZL1 chr1 167721192 167791919 + PCGF3 chr4 705748 770640 + PGK1 chrX 77910739 78129295 + PTPRJ chr11 47980558 48170841 + RAB8A chr19 16111889 16134234 + SAMD4B chr19 39342396 39385710 + SORBS3 chr8 22544986 22575788 + TCF3 chr19 1609290 1652615 - TMEM127 chr2 96248516 96265994 - USP37 chr2 218450251 218568351 - ZIC1 chr3 147393422 147510293 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001349 chr3 152132729 152150709 + hsa_circ_0001605 chr6 42903447 42905047 + hsa_circ_0001146 chr20 34241449 34246936 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC016876.2 chr17 7581964 7584086 - AC135048.1 chr16 30948386 30956511 + DSCAM-AS1 chr21 40383083 40385358 + KCNQ1OT1 chr11 2608328 2699994 - NEAT1 chr11 65422774 65445540 + TUG1 chr22 30969245 30979395 + Display:

Experiment Detail

GEO ID: GSE98181 Sample Source: Blood Source Fraction: Serum Platform: GPL21572 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 2546 Sample treatment protocol: Serum is obtained from coagulated whole blood samples by centrifugation at 3000 rpm for 10 minutes. RNA Extract protocol: RNA was isolated from a 200ul serum aliquot using the miRNeasy Serum Plasma kit with ce-miR-39 spike-in (QIAGEN), QIAcube (QIAGEN) automation, and eluted with 14uL of nuclease-free water. RNA library preparation protocol: Exactly 8ul of RNA was tagged with a Poly-A tail, using an ATP driven reaction from the Affymetrix® FlashTag™ Biotin HSR RNA Labeling Kit.

Reference

PMID: 29348816 Title: Development of a predictive miRNA signature for breast cancer risk among high-risk women. Author: Farina NH, Ramsey JE, Cuke ME, Ahern TP, Shirley DJ, Stein JL, Stein GS, Lian JB, Wood ME Journal: Oncotarget. 2017 Nov 28;8(68):112170-112183. Description: We evaluated the ability of C-miRNAs to identify women most likely to develop breast cancer by profiling miRNA from serum obtained long before diagnosis.